Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naxitamab + allogeneic natural killer cells
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is an investigational combination immunotherapy developed by Memorial Sloan Kettering Cancer Center for the treatment of high-risk neuroblastoma. The regimen consists of allogeneic natural killer (NK) cells administered alongside naxitamab (Hu3F8), a humanized monoclonal antibody that targets the GD2 ganglioside frequently overexpressed on neuroblastoma cells. The therapy is designed to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) by providing a potent source of effector cells (allogeneic NK cells) to interact with the antibody-coated tumor cells. The treatment protocol also includes lymphodepleting chemotherapy with cyclophosphamide and the administration of recombinant interleukin-2 (rIL-2) to promote the expansion and activation of the infused NK cells. This synergistic approach aims to overcome the immune evasion mechanisms of neuroblastoma by combining targeted antibody therapy with donor-derived cellular immunity.
- Other names
- Hu3F8 + NK cellsallogeneic natural killer cellshumanized anti-GD2 antibody Hu3F8
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)GD2
Beyond the preview
Go deeper on naxitamab + allogeneic natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naxitamab + allogeneic natural killer cells.